Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|July 13, 2026

The BioPharm Brief: Regeneration, Responses, and Regulatory Wins

Listen
0:00 / 0:00

Today's BioPharm Brief highlights three regulatory and clinical milestones, including an FDA RMAT designation for a regenerative therapy in osteoarthritis, promising rectal cancer data from GSK's AZUR-1 study, and a new perioperative treatment option for muscle-invasive bladder cancer.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today, we're looking at three stories that could reshape treatment across orthopedics and oncology, from a regenerative medicine designation and encouraging immunotherapy data to an FDA approval that establishes a new treatment option for bladder cancer.

Our first story focuses on regenerative medicine. Enlivex has received FDA Regenerative Medicine Advanced Therapy, or RMAT, designation for Allocetra, its investigational immunotherapy for age-related symptomatic knee osteoarthritis in adults aged 64 years and older. The designation was supported by phase I/IIa data showing statistically significant improvements in pain and function compared with placebo, with benefits lasting at least six months. RMAT status provides opportunities for closer FDA interaction and may support an accelerated development pathway for a disease with limited treatment options beyond symptom management.

Next, GSK reported encouraging results from its phase II AZUR-1 trial evaluating dostarlimab in patients with mismatch repair-deficient, locally advanced rectal cancer. The study met its primary endpoint, with a clinically meaningful proportion of patients achieving a complete clinical response that was sustained for at least one year, allowing many to avoid surgery and chemoradiation. The findings add to growing evidence supporting immunotherapy as a potential organ-preserving treatment strategy for selected patients with rectal cancer.

Finally, the FDA has approved Padcev, or enfortumab vedotin, in combination with Keytruda, or pembrolizumab, as the first perioperative platinum-free regimen for adults with muscle-invasive bladder cancer regardless of cisplatin eligibility. The approval expands access to a treatment option that can be given both before and after surgery and reflects continued momentum toward antibody-drug conjugate and immunotherapy combinations in earlier stages of cancer treatment.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • RMAT designation boosts regenerative medicine for osteoarthritis.
  • Immunotherapy advances earlier in cancer treatment.
  • Combination therapies continue to redefine bladder cancer care.

Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.